Xbrane Nears FDA Decision for Lucamzi Biosimilar
STOCKHOLM, Sweden, June 3, 2026 Xbrane Biopharma AB has reached a significant regulatory milestone after the U.S. Food and...
Retinal Diseases
Advertisement
Teva Launches AHZANTIVE Biosimilar to Eylea Across Europe
TEL AVIV, Israel, June 4, 2026 Teva Pharmaceutical Industries Ltd. has announced the European launch of AHZANTIVE® (aflibercept), an...
Opus Genetics Enters FDA RDEP Program for OPGx-LCA5
RESEARCH TRIANGLE PARK, N.C. – May 4, 2026 Opus Genetics Inc. has announced that its investigational gene therapy OPGx-LCA5...
Ocugen OCU410 Gene Therapy Cuts GA Progression
MALVERN, Pennsylvania, USA | March 24, 2026 In a major breakthrough for retinal disease treatment, Ocugen, Inc. has announced...
KSI-101 Phase 1b Data Advance Inflammatory Macular Therapy
PALO ALTO, Calif., Feb. 4, 2026 —Kodiak Sciences Inc. announced that final end-of-study Phase 1b APEX clinical results evaluating...
Advertisements
Kiora Pharmaceuticals Advances Dual Phase 2 Retinal Trials with FDA-Backed Innovation
Dateline — Encinitas, California, November 8, 2024:Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced its third-quarter 2024 results alongside significant progress...
Celltrion Secures FDA Approval for EYDENZELT® in Multiple Retinal Diseases
INCHEON, South Korea, Oct. 9, 2025 — Celltrion, Inc., a global biopharmaceutical innovator, announced that the U.S. Food and...
Kodiak’s KSI-101 Delivers Promising Data in Retinal Disease Study
PALO ALTO, Calif., Sept. 15, 2025 – Kodiak Sciences Inc. (Nasdaq: KOD), a retina-focused biotechnology company, announced new data...
Advertisement
